The key clinical results of Xindili monoantigen were published
-
Last Update: 2021-03-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today, Cinda Biopharmaceuticals and Lilly Pharmaceuticals jointly announced the joint development of the Xindili monoanti-anti-secondary treatment of locally advanced or metastatic esophageal squamous cancer (ORIENT-) at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) in the form of a wall-to-wall discussion. 2) Key clinical findings (summary no. 4511, Wall No. 119, Friday, May 29, 2020 8:00 AM - 11:00 AM Central Time).
The ORIENT-2 study, published at asCO's annual meeting, was a randomized, open, multicenter, Phase II controlled clinical study comparing the efficacy and safety of cinnamo monoanti and chemotherapy (yew alcohol or elliptical) in patients with advanced/metastatic esophageal squamous cancer who failed first-line treatment. A total of 190 subjects in this study were treated with a 1:1 randomized group of cyndili monoantigen injections or chemotherapy drugs (yew alcohol or elixir). The main study endpoint is total lifetime (OS).As of August 2, 2019, in the Intentional Analysis (ITT) population, Hindili monoantigen significantly extended the total patient lifespan (HR-0.70) compared to yew alcohol/iliticol, The mid-OS in the Syndilly monoantigroup and the chemotherapy group was 7.2 months and 6.2 months, respectively, and the 12-month OS rate was 37.4% and 21.4%, respectively. The safety characteristics of Syndicly monoantigen in esophageal squamous cancer are similar to among other tumors. (U.S. News Agency)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
